Article information
Full text is only aviable in PDF
Bibliografía
[1.]
R. Vidal, M. Miravitlles, Grupo de Estudio del Déficit de Alfa-1-Antitripsina.
Informe del Registro Español de Pacientes con Déficit de Alfa-1-Antitripsina.
Arch Bronconeumol, 31 (1995), pp. 299-302
[2.]
N. Anthonisen.
Design of a clinical trial to test a treatment of the underlying cause of emphysema.
Ann NY Acad Sci, 624 (1991), pp. 31-34
[3.]
J.W. Hay, E.D. Robin.
Cost-effectiveness of alpha-1-antitrypsin replacement therapy in treatment of congenital chronic obstructive pulmonary disease.
Am J Public Health, 81 (1991), pp. 427-433
[4.]
A. Dirksen, F. Madsen, C.S. Ulrik, A. Kok-Jensen, T. Heckscher, K. Viskum, et al.
A randomized placebo-controlled pilot study of alpha-1-protease inhibitor replacement therapy monitored by daily spirometry.
Am Rev Respir Dis, 147 (1993), pp. 325A
[5.]
F. Madsen, C.S. Ulrik, A. Driksen, K.K. Hansen, N.H. Nielsen, L. Frolund, et al.
Patient-administered sequential spirometry in healthy volunteers and patients with alpha-1-antitrypsin deficiency.
Res Med, 90 (1996), pp. 131-138
[6.]
M.D. Wewers, M.A. Casolaro, R.G. Crystal.
Comparison of alpha-1-antitrypsin levels and antineutrophil elastase capacity of blood and lung in a patient with the alpha-1-antitrypsin phenotype null-null before and during alpha-1-antitrypsin augmentation therapy.
Am Rev RespirDis, 135 (1987), pp. 539-543
[7.]
M.D. Wewers, M.A. Casolaro, S.E. Sellers, S.C. Swayze, K.M. McPhaul, J.T. Wittes, et al.
Replacement therapy for alpha-1-antitrypsin deficiency associated with emphysema.
N Engl J Med, 316 (1987), pp. 1.055-1.062
[8.]
M. Miravitlles, R. Vidal, J. De Gracia.
Enfisema por déficit de alfa-1-antitripsina. Situación actual y nuevas perspectivas para el tratamiento.
Arch Bronconeumol, 28 (1992), pp. 296-302
[9.]
R.C. Hubbard, S. Sellers, D. Czerski, L. Stephens, R.G. Crystal.
Biochemical efficacy and safety on monthly augmentation therapy for alpha-1-antitrypsin deficiency.
JAMA, 260 (1988), pp. 1.259-1.264
[10.]
P.J. Stone, T.A. Morris III, C. Franzblau, G.L. Snider.
Preliminary evidence that augmentation therapy diminishes degradation of crosslinked elastin in alpha-1-antitrypsin-deficient humans.
Respiration, 62 (1995), pp. 76-79
[11.]
D.J. Gottlieb, P.J. Stone, D. Sparrow, M.E. Gale, S.T. Weiss, G.L. Snider, et al.
Urinary desmosine excretion in smokers with and without rapid decline of lung function: The Normative Aging Study.
Am J respir Crit Care Med, 154 (1996), pp. 1.290-1.295
[12.]
American Thoracic Society.
Guidelines for the approach to the patient with severe hereditary alpha-1-antitrypsin deficiency.
Am Rev Respir Dis, 140 (1989), pp. 1.494-1.497
[13.]
R. Vidal, M. Miravitlles, X. De Gracia, B. Gallego, F. Morell.
Tratamiento sustitutivo del enfisema por déficit de alfa-1-antitripsina.
Med Clin (Barc), 96 (1991), pp. 180-182
[14.]
N. Konietzko.
Alpha-1-antitrypsin substitution treatment or prevention of emphysema.
Lung, 168 (1990), pp. 592-598
[15.]
P. Caries, J. Constans, M.C. Pujazon, J. Arnaud, D. Lauque, M. Goudemand.
Bilan à deux ans du traitement substitutif de 1’emphyséme PiZZ par l’alpha-1-antitrypsine.
Neuf cas. Presse Méd, 19 (1990), pp. 514-518
[16.]
A.F. Barker, F. Siemsen, D. Pasley, R. D'Silva, S. Buist.
Replacement therapy for hereditary alpha-1-antitrypsin deficiency. A program for long-term administration.
Chest, 105 (1994), pp. 1.406-1.410
[17.]
M. Miravitlles, R. Vidal, M. Torrella, J.M. Bofill, M. Cotrina, J. De Gracia.
Evaluación del tratamiento sustitutivo del enfisema por déficit de alfa-1-antitripsina.
Arch Bronconeumol, 30 (1994), pp. 479-484
[18.]
M. Schwaiblmair, C. Volgemeier, G. Fruhmann.
Long-term augmentation therapy in twenty patients with severe alpha-1-antitrypsin deficiency-Three-year follow-up.
Respiration, 64 (1997), pp. 10-15
[19.]
B. Burrows, M.D. Lebowitz, A.E. Camilli, R.J. Knudson.
Longitudinal changes in forced expiratory volume in one second in adults.
Am Rev Respir Dis, 133 (1986), pp. 974-980
[20.]
N.G. McElvaney, J.K. Stoller, A.S. Buist, U.B.S. Prakash, M.L. Brantly, M.D. Schluchter, et al.
Baseline characteristics of enrollees in the National Hearth Lung and Blood Institute Registry ofalpha-1-antitrypsin deficiency.
Chest, 111 (1997), pp. 394-403
[21.]
J. De Gracia, M. Vendrell, L. Guarner, R. Vidal, M. Miravitlles, C. Mayordomo, et al.
Utilización de gammaglobulina humana en el tratamiento de la inmunodeficiencia común variable.
Med Clin (Barc), 104 (1995), pp. 201-206
[22.]
B. Wallaert, B. Gressier, C.H. Marquette, P. Gosset, M. Remy-Jardin, J. Mizon, et al.
Inactivation of alpha-1-proteinase inhibitor by alveolar inflammatory cells from smoking patients with or without emphysema.
Am Rev Respir Dis, 147 (1993), pp. 1.537-1.543
[23.]
A. Yoshioka, T. Betsuyaku, M. Nishimura, K. Miyamoto, T. Kondo, Y. Kawakami.
Excessive neutrophil elastase in bronchoalveolar lavage fluid in subclinical emphysema.
Am J Respir Crit Care Med, 152 (1995), pp. 2.127-2.132
[24.]
E.N. Kosmas, D. Zorpidcu, V. Vassilareas, T. Roussou, S. Michaelides.
Decreased C4 complement component serum levéis correlate with the degree of emphysema in patients with chronic bronchitis.
Chest, 112 (1997), pp. 341-347
[25.]
M. Wencker, J. Denker, N. Konietzko.
Serial measurements of FEV1 over 12 years in a patient with alpha-1-protease inhibitor deficiency: influence of augmentation therapy and infections.
Respiration, 61 (1994), pp. 195-198
[26.]
N. Seersholm, A. Kok-Jensen, A. Dirksen.
Survival of patients with severe alpha-1-antitrypsin deficiency with special reference to non-index cases.
Thorax, 94 (1994), pp. 695-698
[27.]
N. Seersholm, A. Kok-Jensen.
Survival in relation to lung function and smoking cessation in patients with severe hereditary alpha-1 -antitrypsin deficiency.
Am J Respir Crit Care Med, 151 (1995), pp. 369-373
[28.]
R. Vidal, M. Miravitlles, R. Jardí, M. Torrella, F. Rodríguez-Frías, P. Moral, et al.
Estudio de la frecuencia de los diferentes fenotipos de la alfa-1-antitripsina en una población de Barcelona.
Med Clin (Barc), 107 (1996), pp. 211-214
[29.]
M. Miravitlles, J.C. Barros-Tizón, A. Bustamante, F. Casas, J. Palicio, P. España, et al.
Repon of the Spanish Registry of patients with alpha-1-antitrypsin deficiency.
Eur Respir J, 10 (1997), pp. 391
[30.]
M. Brenner, R. Yusen, R. McKenna, F. Sciurba, A.F. Gelb, R. Fischel, et al.
Lung volume reduction surgery for emphysema.
Chest, 110 (1996), pp. 205-218
[31.]
Grupo de Expertos SEPAR.
Impacto social y económico de la EPOC en España. Bernard Krief.
Farmacoeconomía, 5 (1996), pp. 8-19
Copyright © 1998. Sociedad Española de Neumología y Cirugía Torácica
